Former Pfizer president of global R&D John LaMattina, PhD, has joined Boston-based venture firm PureTech Ventures as senior partner. The move follows yesterday’s announcement that Pfizer was splitting leadership of its R&D operations into a biotherapeutics division, headed by Mikael Dolsten, and a pharmatherapeutics division, headed by Martin Mackay. LaMattina spent 30 years at Pfizer.
Santen CEO Adrienne Graves has been appointed to the board of directors of the Glaucoma Research Foundation. Graves leads the US subsidiary of Japan’s Santen Pharmaceutical Co., a leading manufacturer of prescription ophthalmic drugs globally.
